Top Markets
#1 Black Phoenix Black Phoenix +198.52%
#2 Islamic Coin Islamic Coin +158.00%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +45.63%
#5 BasedHype BasedHype +39.57%
#6 Acurast Acurast +23.87%
#7 Cryptopia Cryptopia +21.79%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +21.41%
#9 Moolah Moolah +17.16%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Imaging Biometrics Ltd. Imaging Biometrics Ltd.

Imaging Biometrics Ltd.

IBAI
Rank in Stocks #41380
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier,... Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Share Price
$0.01088561
Market Cap
$26.86K
Change (1 day)
14.29%
Change (1 year)
33.61%
Country
JE
Trade Imaging Biometrics Ltd. (IBAI)

Category

Healthcare
P/E ratio for Imaging Biometrics Ltd. (IBAI)
P/E ratio as of 2026 TTM: 0
According to Imaging Biometrics Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Imaging Biometrics Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 19.55 -
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 72.09 -
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 41.76 -
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 -30.68 -
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.